Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Randall M Stevens

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
The New England Journal of Medicine|April 16, 2015
Apremilast for Behçet's syndrome--a phase 2, placebo-controlled studyGulen Hatemi, Melike Melikoglu, Recep Tunc, et al.
The Journal of Rheumatology|July 17, 2016
A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 TrialMaurizio Cutolo, Gary E Myerson, Roy M Fleischmann, et al.
Annals of the Rheumatic Diseases|March 6, 2014
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitorArthur Kavanaugh, Philip J Mease, Juan J Gomez-Reino, et al.
Journal of the American Academy of Dermatology|June 20, 2015
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)Kim Papp, Kristian Reich, Craig L Leonardi, et al.
Clinical and Translational Medicine|September 4, 2016
JNK inhibition reduces lung remodeling and pulmonary fibrotic systemic markersJos L J van der Velden, Ying Ye, James D Nolin, et al.
Seminars in Arthritis and Rheumatism|November 2, 2023
Stakeholder endorsement advancing the implementation of a patient-reported domain for harms in rheumatology clinical trials: Outcome of the OMERACT Safety Working GroupDorthe B Berthelsen, Lee S Simon, John P A Ioannidis, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
The New England Journal of Medicine|April 16, 2015
Apremilast for Behçet's syndrome--a phase 2, placebo-controlled studyGulen Hatemi, Melike Melikoglu, Recep Tunc, et al.
The Journal of Rheumatology|July 17, 2016
A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 TrialMaurizio Cutolo, Gary E Myerson, Roy M Fleischmann, et al.
Annals of the Rheumatic Diseases|March 6, 2014
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitorArthur Kavanaugh, Philip J Mease, Juan J Gomez-Reino, et al.
Journal of the American Academy of Dermatology|June 20, 2015
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)Kim Papp, Kristian Reich, Craig L Leonardi, et al.
Clinical and Translational Medicine|September 4, 2016
JNK inhibition reduces lung remodeling and pulmonary fibrotic systemic markersJos L J van der Velden, Ying Ye, James D Nolin, et al.
Seminars in Arthritis and Rheumatism|November 2, 2023
Stakeholder endorsement advancing the implementation of a patient-reported domain for harms in rheumatology clinical trials: Outcome of the OMERACT Safety Working GroupDorthe B Berthelsen, Lee S Simon, John P A Ioannidis, et al.
Pageof 2